454 Results

FDA approves Siliq (brodalumab) to treat moderate-to-severe plaque psoriasis.-Valeant Pharma Intl.

 Added 6 days ago

The FDA has approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq...

EU approves Votubia (everolimus) as adjunctive treatment for partial-onset seizures associated with tuberous sclerosis complex- Novartis

 Added 21 days ago

Novartis announced that the European Commission has approved Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two...

Phase III pivotal trial results for SB 204 (nitric oxide) in treatment of acne vulgaris shows some benefits- Novan

 Added 25 days ago

Novan announced top-line results from the Company’s two, replicate Phase III pivotal clinical trials for SB 204 (nitric oxide) in...

Rhofade cream (oxymetazoline HCI cream 1.0%) approved by FDA for persistent facial erythema associated with rosacea- Allergan

 Added 1 month ago

Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...

Phase III (AB06006) study of masitinib in severe indolent systemic mastocytosis is published in The Lancet- AB Science SA

 Added 1 month ago

AB Science SA announced that results from the pivotal phase III (AB06006) study of masitinib in severe indolent systemic mastocytosis...

Phase III trial of CHS 1420, (adalimumab biosimilar) meets primary endpoint in psoriasis- Coherus BioSciences

 Added 1 month ago

Coherus BioSciences reported results from an ongoing 3-Part, Phase III clinical study of CHS 1420, (adalimumab biosimilar) candidate in psoriasis....

Second successful Phase III trial of IDP 118 (halobetasol propionate and tazarotene)lotion to treat plaque psoriasis.- Valeant Pharma International.

 Added 1 month ago

Valeant Pharmaceuticals International, Inc.announced positive results from a second confirmatory pivotal Phase III, multicenter double-blind, randomized, vehicle-controlled clinical study to...

UK's NICE recommends use of Cosentyx (secukinumab) in active psoriatic arthritis- Novartis

 Added 1 month ago

The UK's National Institute for Health and Care Excellence is supporting use of Cosentyx (secukinumab), from Novartis, alone, or in...

UK's NICE recommends use of Cimzia (certolizumab pegol) in active psoriatic arthritis- UCB

 Added 1 month ago

The National Institute for Health and Care Excellence is supporting use of Cimzia (certolizumab pegol), from UCB, alone, or in...

Sun Pharma acquires Odomzo (sonidegib) an approved treatment for basal cell carcinoma from Novartis.

 Added 1 month ago

Sun Pharmaceutical Industries Ltd and its subsidiaries or associate companies announced its plans to acquire a branded oncology product, Odomzo...

Load more